Gout Therapeutics Market is expected to reach US$ 5.55 billion by 2033 | Top key players - Amgen Inc., Lupin, AstraZeneca

Market Size and Growth:

The Global Gout Therapeutics Market size reached US$ 2.94 billion in 2023, with a rise to US$ 3.13 billion in 2024, and is expected to reach US$ 5.55 billion by 2033, growing at a CAGR of 7.4% during the forecast period 2025-2033. The Market is driven by the rising prevalence of gout due to changing lifestyles, increasing obesity rates, and advancements in novel urate-lowering therapies. According to DataM Intelligence

To Download a Free Sample PDF (Use Corporate email ID to Get Higher Priority) at: https://datamintelligence.com/download-sample/gout-therapeutics-market?sz

The Gout Therapeutics Market encompasses the development, production, and commercialization of drugs and therapies aimed at treating gout a form of inflammatory arthritis caused by uric acid crystal buildup in joints. It includes urate-lowering agents, anti-inflammatory drugs, and biologics designed to manage acute attacks, reduce uric acid levels, and prevent disease recurrence.

Industry Recent Developments: United States

✅ September 2025: The gout therapeutics pipeline expanded significantly, with over 20 companies developing more than 25 novel gout therapies, addressing unmet medical needs in gout treatment. This expansion reflects active innovation and new drug launch activities in the US market.

✅ September 2025: The chronic gout market in the US is expected to maintain stable growth through 2034, driven by new drug classes such as mTOR inhibitors and URAT1 inhibitors. Upcoming therapies like NASP, Pozdeutinurad, and Lingdolinurad are anticipated to significantly impact the market.

✅ October 2025: Atom Therapeutics enrolled the first patient in a multicenter Phase 2 acute gout flare trial, including sites in the US, demonstrating clinical progress of novel oral drugs for chronic and acute gout management.

Industry Recent Developments: Japan

✅ September 2025: Global Phase IIb/III clinical trials of Lingdolinurad, a novel oral gout drug by Atom Therapeutics, progressed in Japan as part of global development efforts.

✅ 2025 (general outlook): Japan gout therapeutics market projected to grow at a 7.9% CAGR, driven by segments such as NSAIDs and urate lowering agents with increasing adoption of advanced treatments.

✅ September 2025: Growing awareness and early diagnosis programs in Japan emphasize lifestyle changes, diet management, and medication adherence, supporting market growth alongside new drug launches in chronic gout management.

Get Customization in the report as per your requirements + Exclusive Bundle & Multi-User Discounts: https://datamintelligence.com/customize/gout-therapeutics-market?sz

Regulatory Approvals & Notable regulatory events (2025):

✅ Dotinurad (URECE / dotinurad family) - approvals / launches in some APAC markets during 2024-2025 and continued regulatory/clinical progress in 2025:

✅ Eisai / partners reported approvals/launches for dotinurad (Urece) in Philippines (Feb 2025) and earlier approvals in Thailand (Sept 2024); China activity/launch also reported in 2025. Crystalys / Fortress and partners were advancing dotinurad in global Phase-3 activity in 2025.

✅ Clinical/regulatory interactions in the U.S. (2025) - several companies entered formal FDA interactions (Type C meetings, NDA discussions) and advanced Phase-3 programs rather than receiving approvals. Example: XORTX announced that it commenced NDA discussions with the FDA in 2025 for its gout program.

✅ Pipeline → regulatory push - 2025 saw multiple URAT1 inhibitors and other novel urate-lowering agents move into pivotal/Phase-3 studies and sponsor-FDA discussions, indicating that regulatory submissions are being prepared but not yet approved in the U.S. in 2025.

Major Key Players:

Takeda Pharmaceutical Company Limited
Novartis Pharmaceuticals Corporation
Amgen Inc.
Lupin
AstraZeneca.

Segments Covered in the Gout Therapeutics Market:

By Disease Type: Primary Gout, Secondary Gout.

By Drug Class: Non-Steroidal Anti-inflammatory Drugs (NSAIDs), Colchicine, Corticosteroids, Uricosuric Medications, Others.

By Distribution Channel: Hospital Pharmacies, Drug Stores, E-commerce, Others.

Regional Analysis for Gout Therapeutics Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Looking For Full Report? Get it Here: https://www.datamintelligence.com/buy-now-page?report=gout-therapeutics-market

Chapter Outline:

⏩ Market Overview: It contains five chapters, as well as information about the research scope, major manufacturers covered, market segments, Gout Therapeutics market segments, study objectives, and years considered.

⏩ Market Landscape: The competition in the Global Gout Therapeutics Market is evaluated here in terms of value, turnover, revenues, and market share by organization, as well as market rate, competitive landscape, and recent developments, transaction, growth, sale, and market shares of top companies.

⏩ Companies Profiles: The global Gout Therapeutics market's leading players are studied based on sales, main products, gross profit margin, revenue, price, and growth production.

⏩ Market Outlook by Region: The report goes through gross margin, sales, income, supply, market share, CAGR, and market size by region in this segment. North America, Europe, Asia Pacific, Middle East & Africa, and South America are among the regions and countries studied in depth in this study.

⏩ Market Segments: It contains the deep research study which interprets how different end-user/application/type segments contribute to the Gout Therapeutics Market.

⏩ Market Forecast: Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type.

⏩ Research Findings: This section of the report showcases the findings and analysis of the report.

⏩ Conclusion: This portion of the report is the last section of the report where the conclusion of the research study is provided.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Frequently asked questions:

➠ What is the global sales value, production value, consumption value, import and export of Gout Therapeutics market?

➠ Who are the global key manufacturers of the Gout Therapeutics Industry? How is their operating situation (capacity, production, sales, price, cost, gross, and revenue)?

➠ What are the Gout Therapeutics market opportunities and threats faced by the vendors in the global Gout Therapeutics Industry?

➠ Which application/end-user or product type may seek incremental growth prospects? What is the market share of each type and application?

➠ What focused approach and constraints are holding the Gout Therapeutics market?

➠ What are the different sales, marketing, and distribution channels in the global industry?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.